Use of generics and biosimilars instead of originator drugs reduces the cost of cancer treatment without discernible adverse impact on the quality of care, according to an analysis of the Oncology Care Model.
The study showed that “even small shifts in utilization towards lower cost alternatives can generate a significant reduction in the total cost of care,” reported Erica Feinberg, PharmD, the senior clinical data analyst at The US Oncology Network, in The Woodlands,